Kurs & Likviditet
|2022-06-09||Ordinarie utdelning EXTX 0.00 NOK|
|2021-05-14||Ordinarie utdelning EXTX 0.00 NOK|
|2020-07-27||Split EXTX 1:250|
|2020-07-24||Extra Bolagsstämma 2020|
EXTX: EXACT THERAPEUTICS SELECTED AS NORWEGIAN FLAGSHIP COMPANY AT NORDIC LIFE SCIENCE DAYS CONFERENCE 2021
OSLO/LONDON, APRIL 20th 2021: EXACT THERAPEUTICS AS ("EXACT-Tx" or the
"Company"), a clinical stage precision medicine company utilizing Acoustic
Cluster Therapy (ACT®) across multiple therapeutic areas, today announced that
it has been selected as the Norwegian flagship company at the Nordic Life
Science ("NLS") days conference with CEO, Dr Rafiq Hasan, participating in the
opening plenary. NLS Days is the largest Nordic partnering conference dedicated
to the life science industry and is taking place April 20-23.
"It is a privilege to be selected as the flagship company from Norway at the NLS
Days 2021 meeting alongside other great Nordic companies", said Dr Rafiq Hasan,
CEO of EXACT Therapeutics AS. "NLS Days 2021 is a great opportunity to learn
about the strong innovation emerging from the Nordic region, as well as to share
experiences and best practices. The conference comes at an exciting time for the
Company with our ongoing Phase I ACTIVATE study, continued expansion in both
Norway and the UK with key appointments, the opening of a new research facility
and expanding technology collaboration with GE Healthcare."
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com
For more information contact:
Dr Rafiq Hasan, CEO EXACT Therapeutics Rafiq@exact-tx.com